Omburtamab

Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276) . Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect) . Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) [1][2].